AnaptysBio's Ulcerative Colitis Drug Trial Fails

AnaptysBios ulcerative colitis drug trial, rosnilimab, failed to meet main goals, leading to a twenty percent stock drop. Despite safety and patient tolerance, the drug showed no significant improvement for moderate to severe ulcerative colitis patients after twelve weeks. The company decided to discontinue the trial, saving at least ten million dollars. AnaptysBio plans to separate drug development from royalty assets by 2026, expecting around three hundred million dollars by the end of 2025, including a seventy-five million dollar payment from GSK.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.